15353-j-veluchamy

3 HLA independent killing of cervical tumors by UCB-NK cells | 89 15. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 124:783-801, 2006. 16. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S: Functions of natural killer cells. Nat Immunol 9:503-510, 2008. 17. Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L: Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol 44:1582-1592, 2014. 18. Kobayashi A, Greenblatt RM, Anastos K, Minkoff H, Massad LS, YoungM et al. : Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 64:6766-6774, 2004. 19. Textor S, Durst M, Jansen L, Accardi R, Tommasino M, Trunk MJ et al. : Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 123:2343- 2353, 2008. 20. Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH et al. : HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes. Proc Natl Acad Sci U S A 108:10656-10661, 2011. 21. Renoux VM, Bisig B, Langers I, Dortu E, Clemenceau B, Thiry M et al. : Human papillomavirus entry into NK cells requires CD16 expression and triggers cytotoxic activity and cytokine secretion. Eur J Immunol 41:3240-3252, 2011. 22. Jimenez-PerezMI, Jave-Suarez LF, Ortiz-Lazareno PC, Bravo-Cuellar A, Gonzalez-Ramella O, Aguilar- Lemarroy A et al. : Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications. BMC Immunol 13:7, 2012. 23. Arreygue-Garcia NA, Daneri-Navarro A, Del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF et al. : Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 8:16, 2008. 24. Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Duenas MG et al. : Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 9:186, 2009. 25. Spaans VM, Peters AA, Fleuren GJ, Jordanova ES: HLA-E expression in cervical adenocarcinomas: association with improved long-term survival. J Transl Med 10:184, 2012. 26. Gimenes F, Teixeira JJ, de Abreu AL, Souza RP, Pereira MW, da Silva VR et al. : Human leukocyte antigen (HLA)-G and cervical cancer immunoediting: a candidate molecule for therapeutic intervention and prognostic biomarker? Biochim Biophys Acta 1846:576-589, 2014. 27. Cho H, Chung JY, Kim S, Braunschweig T, Kang TH, Kim J et al. : MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer 14:957, 2014. 28. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA et al. : A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13:98-107, 2011.